2). COVID-19 virus is mostly spread from person to person via respiratory droplet transmission, which happens while a person is in close contact with an infected person. This happens via exposure of the host's mucosal surfaces, including nose, mouth, and eyes to the incoming infective droplets (3,4). The covid-19 median incubation duration is expected to be 5.1 days, and most of the patients will progress symptoms in 11.5 days of infection (5). 17.9% of covid-19 patients is estimated to remain asymptomatic (6). However, the symptoms of symptomatic patients commonly include fever, cough, as well as shortness of breath. Sore throat, anosmia, nausea, dysgeusia, anorexia, malaise, diarrhea, and myalgias are reported as less common symptoms (7, 8). RT-PCR was introduced as the standard test for the diagnosis of the virus, however, the importance of chest CT scans in those whose RT-PCR test is false-negative was reported with a sensitivity of 98% (7). Presently, different therapeutic choices are existing for covid-19 including antiviral drugs such as molnupiravir, remdesivir, and paxlovid; anti-SARS-CoV-2 monoclonal antibodies such as bamlanivimab/etesevimab and casirivimab/imdevimab; anti-inflammatory drugs like dexamethasone; and immunomodulators agents such as baricitinib and tocilizumab (9). According to the evidence, older age, suppressed immune systems, presence of underlying cardiovascular, metabolic, and respiratory diseases are risk factors for adverse outcomes (10).Accurate estimation of epidemiological information, in particular infection and mortality rates, demographic information, and comorbidities, is required to decide on